|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Tue., Jan. 26, 6:14 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #22 of 25 |
Slide #22. TCR2 Therapeutics Inc. — Secondary Offering
Company:
TCR2 Therapeutics Inc. (NASDAQ:TCRR)
Date announced:
1/19/2021
Shares Offered:
4,590,164
Date of Pricing:
1/19/2021
Price Per Share:
$30.50
Secondary Offering Details:
TCR2 Therapeutics Inc. (Nasdaq: TCRR) ("TCR2" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offering are to be sold by TCR2. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. -updated 1/19- TCR2 Therapeutics Inc. (Nasdaq: TCRR) ("TCR2" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share. TCR2 also granted the underwriters a 30-day option to purchase up to an additional 688,524 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $140.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by TCR2. The offering is expected to close on or about January 22, 2021, subject to customary closing conditions.
TCR2 Therapeutics is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer by overcoming the limitations of chimeric antigen receptor T cell therapies and engineered T cell therapies that use the full T cell receptor (TCR-T cells). Co.'s TCR Fusion Construct T cells recognize and kill cancer cells by using the entire T cell receptor TCR signaling complex. Co. has clinical trial for TC-210 to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma, and for TC-110 to treat patients with adult acute lymphoblastic leukemia and with aggressive or indolent non-Hodgkin lymphoma.
TCRR SEC Filing Email Alerts Service
Open the TCRR Page at The Online Investor »
|
|||||||||||||||||||||
Open the TCRR Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 81st percentile
(ranked higher than approx. 81% of all stocks covered)
Analysts' Target Price: TCRR Stock Forecast Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.